In therapy, every decision matters. Pharmacgoenomics testing (PGx) has the ability to positively impact the treatment of many patients who require drug therapy for hypertension, dyslipidemia and other cardiovascular risk factors.
Different patients respond in different ways to the same medication. With over 82% of Americans taking at least one medication and 29% on five or more, adverse drug reactions are likely to occur.
Establish a clear understanding of potential drug/gene and drug/drug interaction unique to each patient to build the most effective and safe treatment plan. AccessDX’s PGx analyzes patients’ genotype, phenotype and metabolism, to help prevent adverse drug events, improve overall patient care and decrease healthcare costs.
Don’t expect complicated genomic reports. AccessDX reports are intuitively laid out with every step thoughtfully considered — with the addition of an alternative drug assessment for the most commonly used drugs. The report you receive will be specific to your specialty.
Following the initial diagnostics and reports, our staff is able to review the clinical implications, giving proactive, predictive recommendations to help physicians improve clinical insight and optimize therapy decisions.
We go beyond the report. Following the initial diagnostics and reports, our staff continuously discusses the clinical implications, giving proactive, predictive recommendations to help physicians improve diagnosis and optimize therapy decisions. AccessDX also offers continual monitoring services and provides information on whether drug dosage adjustment is needed. Our PharmD call center is available to all physicians
The following are some of the most common medications affected by drug/gene and drug/drug interaction that patients should be genetically tested for: